THE EFFECTS OF RALOXIFENE ON OSTEOCALCIN, AS A BONE TURNOVER MARKER IN ORCHIECTOMIZED RATS

Basit Öğe Kaydı
dc.contributor.authorSaklamaz, A.
dc.contributor.authorUyulgan, B.
dc.contributor.authorSevin, G.
dc.contributor.authorKebapcilar, L.
dc.contributor.authorYilmaz, O.
dc.contributor.authorCimrin, D.
dc.contributor.authorKumanlioglu, K.
dc.date.accessioned2020-03-26T18:58:37Z
dc.date.available2020-03-26T18:58:37Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground. The aim of the present study was to measure the effects of raloxifene on bone metabolism and strength in orchiectomized male rats. Materials/Methods. Forty-three 4-month-old Wistar albino male rats were used and divided into 3 groups as orchiectomy (ORCX; n=23), sham (n=15), and control (n=5). Raloxifene (10 mg/kg/day) and methylcellulose (0.5 mL/day, as a vehicle treatment) treatments were initiated 2 months after ORCX for 2 months, then the rats were sacrificed. The left femur and fourth lumbar vertebrae (LV4) were measured to assess the effects of the orchiectomy and the raloxifene treatment and maintenance regimens. Bone strength was assessed using a compression test for the vertebrae and a three-point bending test for the femurs (N/mm). Results. Raloxifene increased femoral and vertebral bone strength in osteoporotic rats, but this increase was not statistically significant. Bone strength was found to be 267.44 +/- 18.03 in the femurs of the ORCX-raloxifene group and 246.32 +/- 49.37 in the femurs of the ORCX-C group (p>0.05). Vertebral bone strength was 147.78 +/- 09.51 in the ORCX-raloxifene group and 114.61 +/- 05.93 in ORCX-C group (p=0.488). Raloxifene also increased the femoral and vertebral bone density compared with the control group, but the change was not significant. While raloxifene significantly decreased the serum osteocalcin levels (p=0.007), it did not decrease the carboxyterminal cross-linking telopeptide of bone collagen (CTX) levels significantly (p=0.066). Conclusions. Raloxifene caused a statistically significant decrease in serum osteocalcin levels and a non-significant reduction in NTX levels in orchiectomized rats.en_US
dc.identifier.doi10.4183/aeb.2014.340en_US
dc.identifier.endpage351en_US
dc.identifier.issn1841-0987en_US
dc.identifier.issn1843-066Xen_US
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage340en_US
dc.identifier.urihttps://dx.doi.org/10.4183/aeb.2014.340
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31202
dc.identifier.volume10en_US
dc.identifier.wosWOS:000339535700003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherEDITURA ACAD ROMANEen_US
dc.relation.ispartofACTA ENDOCRINOLOGICA-BUCHARESTen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectOsteoporosisen_US
dc.subjectmaleen_US
dc.subjectRaloxifeneen_US
dc.subjectraten_US
dc.titleTHE EFFECTS OF RALOXIFENE ON OSTEOCALCIN, AS A BONE TURNOVER MARKER IN ORCHIECTOMIZED RATSen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu